Nanjing Vishee Medical Technology Co Ltd

Vishee Medical released its 2026 interim report. The company's total operating revenue was 226 million yuan, and net profit attributable to the parent company was 100 million yuan. Net cash inflow from operating activities was 59.2596 million yuan, a decrease of 5.5254 million yuan compared with the same period last year, down 8.53 percent year on year. The company's latest asset-liability ratio was 5.74 percent, gross margin was 66.31 percent, return on equity was 5.92 percent, and diluted earnings per share was 1.05 yuan. The number of shareholders was 8,549, and the top ten shareholders held 65.67 percent of the total share capital.

Weisi Medical released its 2026 interim report. Operating revenue was 226 million yuan, up 7.6% year on year. Net profit attributable to the parent was 100 million yuan, up 44.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 67.04 million yuan, up 5.5% year on year. Net operating cash flow was 59.26 million yuan, down 8.5% year on year. Fully diluted earnings per share was 1.05 yuan. In the second quarter, operating revenue was 120 million yuan, up 5.1% year on year. Net profit attributable to the parent was 38.55 million yuan, up 6.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 33.98 million yuan, up 2.9% year on year. Earnings per share was 0.4025 yuan. As of the end of the second quarter, total assets were 1.794 billion yuan, down 6.02% from the end of the previous year. Net assets attributable to the parent were 1.691 billion yuan, down 0.1% from the end of the previous year. The company continues to enrich its products and solutions in the rehabilitation medicine field, mainly covering pelvic floor and postpartum rehabilitation, mental and psychological rehabilitation, neurological rehabilitation, and pediatric rehabilitation, while actively expanding into medical aesthetics with optoelectronic devices and urology, and plans to extend its product portfolio to international markets.

Brain-computer interface technology is accelerating its move from the laboratory into clinical and consumer markets. The global market is expected to exceed 360 billion yuan by 2035, with China likely to account for more than 30 percent of that share. Neuralink has announced completion of the world's first brain-computer interface surgery implanted through the dura mater, while China's first subdural implantable brain-computer interface system has also begun national Class III medical device registration clinical trials. Companies listed in both A-share and Hong Kong markets, such as Wision Medical, Sanbo Brain Hospital, and MicroPort NeuroTech, have already achieved commercial revenue through non-invasive rehabilitation, clinical data assets, and implantable products. On the policy front, brain-computer interfaces have been included in the future industries section of the 15th Five-Year Plan. Beijing, Shanghai, and Guangdong have introduced targeted support policies, and an industry standardization technical committee has also been established. Institutions expect 2027 to become the first year of commercial explosion for brain-computer interfaces.